PCSK9 and diabetes mellitus: Subgroup analyses from the ODYSSEY OUTCOMES, FOURIER, and PROFICIO phase III trials revealed substantial reductions in plasma LDL cholesterol levels among patients with diabetes receiving PCSK9 inhibitors compared to placebo [130].